CTLA4 and neoplasm: The advent of the so-called immunotherapy in oncology, in particular, antibodies against PD-1, PD-L1, and CTLA-4, have significantly modified the treatment, and consequently the history of many cancers, especially cancers with elevated tumor mutational burden, above all, neoplasms with MMRd/MSI [78,79].